Biovica will attend the ASCO (American Society of Clinical Oncology) Annual Meeting, an event that brings together 30 000 global oncology professionals. During ASCO Biovica will meet Pharma companies and oncologists to share the latest insights from the ongoing clinical trial programme and collaborations. Biovica has also been invited to present the latest DiviTum® data at the BIG/IBCSG investigators meeting for the PYTHIA study.
“At ASCO we look forward to meet our clinical research partners and expand our collaborations with drug developers. ASCO is the largest meeting for clinical cancer studies in the world and our presence is important as additional positive clinical results with DiviTum® has become available. Our aim is to increase the availability of the DiviTum® technology in the development of new cancer drugs and for patients, so they get the best possible treatment and efficacy evaluation.” says Anders Rylander, CEO Biovica.